Vaniprevir

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Product Specifications

CAS Number

[923590-37-8]

Product Name Alternative

MK-7009

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

HCV; HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/vaniprevir.html

Purity

99.60

Solubility

10 mM in DMSO

Smiles

O=S(NC([C@@]1(NC([C@H]2N(C([C@@H](NC(OCC(CCCC3)(C)C)=O)C(C)(C)C)=O)C[C@H](OC(N4CC5=C3C=CC=C5C4)=O)C2)=O)C[C@H]1CC)=O)(C6CC6)=O

Molecular Formula

C38H55N5O9S

Molecular Weight

757.94

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Liverton, Nigel J.; Carroll, Steven S.; Di Muzio, Jillian; .MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrobial Agents and Chemotherapy (2009), Volume Date 2010, 54 (1), 305-311.|[2]Kong J, Chen CY, Balsells-Padros J, Cao Y, Dunn RF, Dolman SJ, Janey J, Li H, Zacuto MJ.Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.J Org Chem. 2012 Apr 20;77 (8) :3820-8. Epub 2012 Apr 10.|[3]Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group.Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na?ve patients with chronic hepatitis C: A randomized phase II study.Hepatology. 2012 Sep;56 (3) :884-893.|[4]Song ZJ, Tellers DM, Journet M, Kuethe JT, Lieberman D, Humphrey G, Zhang F, Peng Z, Waters MS, Zewge D, Nolting A, Zhao D, Reamer RA, Dormer PG, Belyk KM, Davies IW, Devine PN, Tschaen DM.Synthesis of vaniprevir (MK-7009) : lactamization to prepare a 20-membered [corrected] macrocycle.J Org Chem. 2011 Oct 7;76 (19) :7804-15. Epub 2011 Aug 31.|[5]McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ.Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.J Med Chem. 2010 Mar 25;53 (6) :2443-63.